Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

157 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Isavuconazole Treatment in a Mixed Patient Cohort with Invasive Fungal Infections: Outcome, Tolerability and Clinical Implications of Isavuconazole Plasma Concentrations.
Zurl C, Waller M, Schwameis F, Muhr T, Bauer N, Zollner-Schwetz I, Valentin T, Meinitzer A, Ullrich E, Wunsch S, Hoenigl M, Grinschgl Y, Prattes J, Oulhaj A, Krause R. Zurl C, et al. Among authors: ullrich e. J Fungi (Basel). 2020 Jun 22;6(2):90. doi: 10.3390/jof6020090. J Fungi (Basel). 2020. PMID: 32580296 Free PMC article.
Evaluation of host-based molecular markers for the early detection of human sepsis.
Ullrich E, Heidinger P, Soh J, Villanova L, Grabuschnig S, Bachler T, Hirschböck E, Sánchez-Heredero S, Ford B, Sensen M, Rosales Rodriguez I, Schwendenwein D, Neumeister P, Zurl CJ, Krause R, Lorenz Khol J, Sensen CW. Ullrich E, et al. J Biotechnol. 2020 Feb 20;310:80-88. doi: 10.1016/j.jbiotec.2020.01.013. Epub 2020 Feb 1. J Biotechnol. 2020. PMID: 32017954
CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells.
Bexte T, Albinger N, Al Ajami A, Wendel P, Buchinger L, Gessner A, Alzubi J, Särchen V, Vogler M, Rasheed HM, Jung BA, Wolf S, Bhayadia R, Oellerich T, Klusmann JH, Penack O, Möker N, Cathomen T, Rieger MA, Imkeller K, Ullrich E. Bexte T, et al. Among authors: ullrich e. Nat Commun. 2024 Sep 30;15(1):8439. doi: 10.1038/s41467-024-52388-1. Nat Commun. 2024. PMID: 39349459 Free PMC article.
CD16+ as predictive marker for early relapse in aggressive B-NHL/DLBCL patients.
Zöphel S, Küchler N, Jansky J, Hoxha C, Schäfer G, Weise JJ, Vialle J, Kaschek L, Stopper G, Eichler H, Yildiz D, Moter A, Wendel P, Ullrich E, Schormann C, Rixecker T, Cetin O, Neumann F, Orth P, Bewarder M, Hoth M, Thurner L, Schwarz EC. Zöphel S, et al. Among authors: ullrich e. Mol Cancer. 2024 Sep 28;23(1):210. doi: 10.1186/s12943-024-02123-7. Mol Cancer. 2024. PMID: 39342291 Free PMC article.
Editorial: Women in cancer immunity and immunotherapy.
Yao M, Ullrich E, Albini A. Yao M, et al. Among authors: ullrich e. Front Immunol. 2024 Aug 21;15:1466010. doi: 10.3389/fimmu.2024.1466010. eCollection 2024. Front Immunol. 2024. PMID: 39234252 Free PMC article. No abstract available.
Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White Patients.
Rios CAO, Qayed M, Etra AM, Reshef R, Newcomb R, Yuhasz N, Hexner EO, Aguayo-Hiraldo P, Merli P, Hogan WJ, Weber D, Kitko CL, Ayuk F, Eder M, Grupp SA, Kraus S, Sandhu K, Ullrich E, Vasova I, Wölfl M, Baez J, Beheshti R, Eng G, Gleich S, Katsivelos N, Kowalyk S, Louloudis IE, Morales G, Spyrou N, Young R, Nakamura R, Levine JE, Ferrara JLM, Akahoshi Y. Rios CAO, et al. Among authors: ullrich e. Transplant Cell Ther. 2024 Nov;30(11):1061.e1-1061.e10. doi: 10.1016/j.jtct.2024.08.019. Epub 2024 Sep 1. Transplant Cell Ther. 2024. PMID: 39222793
157 results